Share
How hormone therapy works
Some cancers depend on hormone signals. Treatment may reduce hormone production or interfere with hormone receptors, proteins that receive hormone signals. Hormone therapy is used particularly in hormone-sensitive breast and prostate cancers and in selected other settings.
Understanding the purpose of endocrine treatment
Hormone therapy treats cancers that depend on particular hormone signals. It does not mean giving the same hormones used for menopausal symptom relief. In early cancer it may reduce the risk of the cancer coming back (recurrence); in advanced disease it may slow growth and control symptoms. A tablet or injection can be an important part of treatment even when it feels less intensive than chemotherapy.
The choice depends on the cancer, receptor findings where relevant, previous treatment and the person’s health. Endocrine therapy may be used on its own or with other treatment. The length of the plan should be explained at the start and reviewed when health, side effects or the disease changes.
Breast cancer
Oestrogen and progesterone receptor findings help guide whether endocrine treatment is relevant. Choice depends on menopausal status, recurrence risk, disease setting and other factors. Options can include medicines that block hormone receptors, medicines that reduce oestrogen production (aromatase inhibitors), and treatment to reduce hormone production by the ovaries (ovarian suppression), where appropriate.
Breast cancer: receptors, menopause and treatment choices
Oestrogen receptor and progesterone receptor results help identify hormone-sensitive breast cancers. Tamoxifen blocks oestrogen action in breast tissue. Aromatase inhibitors reduce oestrogen production and are generally used after menopause, or with ovarian suppression when ovarian function is still present. Other medicines act on the oestrogen receptor in different ways in selected settings.
Ovarian suppression may use injections; permanent removal of the ovaries is a separate decision with lasting implications. Periods stopping during chemotherapy does not always establish permanent menopause. The team may need to review ovarian function when selecting or monitoring treatment.
After surgery, endocrine treatment often continues for several years, with the duration based on recurrence risk, benefits and side effects. In advanced breast cancer, it may be combined with a targeted medicine. The appropriate combination depends on the disease and previous treatment, rather than simply adding more drugs.
Prostate cancer
Androgens are hormones, including testosterone, that can help prostate cancer grow. Androgen deprivation therapy (ADT) lowers testosterone activity through medicines or sometimes surgery. Other medicines may further block androgen signalling. The treatment combination depends on whether disease is localised, recurrent or advanced and on prior treatment.
Prostate cancer: lowering and blocking androgen signals
ADT lowers the hormone stimulation that supports prostate cancer. It may involve injections, tablets or, less commonly, an operation. Other medicines block the androgen receptor or reduce androgen production further. The best combination depends on the cancer setting, fitness and previous treatment.
ADT can accompany radiotherapy in selected localised cancers and is central to many advanced prostate cancer plans. A cancer can progress despite a very low testosterone level; this is called castration-resistant disease. It does not mean every hormone-related treatment has become useless. The oncologist reassesses the overall plan, and baseline ADT often continues with additional treatment.
How it is given and for how long
Treatment can involve daily tablets, scheduled injections or a surgical procedure. Duration differs substantially by cancer and treatment goal. Do not stop treatment because you feel well; discuss troublesome effects so the plan can be reviewed.
Side effects and long-term health
Potential concerns include hot flushes, sexual symptoms, joint symptoms, fatigue, bone loss and changes in how the body uses energy or in the risk of heart and blood-vessel problems. The risks differ between medicines. Your team may assess bone health, activity, weight and relevant blood tests.
Looking after bones, muscles and metabolic health
Some endocrine treatments can reduce bone strength or change muscle mass, weight, blood sugar and cardiovascular risk. Assessment may include bone density and relevant blood tests, depending on the drug and your risk factors. Not everyone needs the same tests or bone-protecting medicines.
Regular activity, including suitable resistance and weight-bearing exercise, can help maintain strength. Discuss exercise adaptations if cancer has spread to your bones, you have pain, or you are at risk of a fracture. Ask about dietary calcium and vitamin D needs rather than starting high-dose supplements. Smoking cessation, blood-pressure care and diabetes management are also part of the plan.
Managing symptoms without giving up treatment
Hot flushes, joint discomfort, fatigue, changes in mood, vaginal dryness or changes in sexual function can affect daily life. Mention them early; they are valid reasons to seek help. Options may include symptom treatments, adjustments or a different endocrine medicine where appropriate.
Do not start hormone replacement, testosterone products or hormone-containing remedies without checking with the cancer team. Vaginal or other local treatments also need an individual discussion. Tell the team about antidepressants and other regular medicines because some combinations, particularly with tamoxifen, need an interaction review.
Symptoms that deserve prompt assessment
Tell the team about unexpected vaginal bleeding, especially after menopause or while taking tamoxifen. A painful swollen leg, sudden breathlessness or chest pain can indicate a blood clot and needs urgent medical assessment. These risks differ between treatments; they do not apply equally to every hormone medicine.
New severe back pain with leg weakness, numbness or bladder or bowel changes needs emergency assessment in someone with cancer. For less urgent symptoms, keep a record and discuss them before stopping tablets or missing injections. A planned review is safer than an unplanned interruption.
Fertility and sexual health
Discuss fertility, pregnancy prevention and menopause-related symptoms before starting. Ask for help with sexual health concerns; these are part of cancer care. Do not use hormone-containing products without checking whether they are suitable.
Monitoring and resistance
Follow-up checks your symptoms, how you are managing the prescribed treatment, any side effects and the cancer using appropriate tests. Hormone therapy may be combined with other treatments, and a change may be needed if the cancer progresses.
Frequently asked questions
Is hormone therapy the same as hormone replacement therapy?
No. Endocrine cancer treatment usually reduces hormone production or blocks a hormone’s action. Hormone replacement is used for a different purpose and may be unsuitable in a hormone-sensitive cancer. Check any hormone-containing product with your team.
Does every breast cancer need hormone therapy?
No. Hormone receptor findings help determine whether it is likely to be useful. Other features are assessed separately, such as human epidermal growth factor receptor 2 (HER2), a protein involved in cell growth. Your doctor should explain the receptor results and how they affect the plan.
Can men with breast cancer receive endocrine treatment?
Yes, when the cancer is hormone-sensitive. The choice and monitoring should be tailored to men with breast cancer rather than assumed to follow every detail of a postmenopausal treatment plan.
Why does menopausal status matter?
It affects where oestrogen is produced and which medicines can suppress it effectively. An aromatase inhibitor alone is generally not appropriate when the ovaries remain active. Ovarian suppression may be needed as part of the plan.
My periods stopped during chemotherapy. Am I definitely menopausal?
Not necessarily. Ovarian function can recover. Tell the team about any return of periods or other changes, and follow their advice about testing and contraception.
Why continue treatment for years if the cancer was removed?
After surgery, additional (adjuvant) endocrine treatment aims to reduce the chance of cancer returning from cells that may remain but are too small to see on scans. There may be no visible tumour to measure. The duration reflects your recurrence risk and the balance of benefit and side effects.
Can I stop because I feel well?
Do not stop on that basis alone. Feeling well may be expected while treatment reduces future risk or controls disease. Discuss your reasons with the team so that benefits, side effects and alternatives can be reviewed.
What can be done about joint pain or hot flushes?
Tell the team how symptoms affect sleep, walking or daily tasks. Activity adjustments, symptom treatments or a change of medicine may help. Persistent or unusual pain should be assessed rather than automatically attributed to treatment.
Will treatment weaken my bones?
Some treatments can increase bone loss, but the degree of risk varies. Your team may recommend a bone-health assessment and preventive measures. Do not assume everyone needs the same supplements or injections.
Will hormone therapy affect sexual function?
It can affect desire, erections, vaginal comfort and other aspects of sexual wellbeing. These concerns are part of routine cancer care. Ask about safe symptom treatments, counselling or referral rather than coping alone.
Can I become pregnant or father a child during treatment?
Fertility may be affected, but reduced fertility is not reliable contraception. Some medicines can harm a developing baby. Discuss preservation and drug-specific pregnancy precautions before treatment and before any planned pregnancy.
What should I do after a missed tablet or injection?
Follow the instructions for your medicine and contact the team if uncertain. Do not double tablets without advice. If an injection appointment is missed, arrange guidance promptly because maintaining suppression may depend on its timing.
Can I take supplements or medicines for menopause symptoms?
Have the exact product checked first, including herbal or hormone-containing products. Some medicines interact with endocrine treatment. The team can help identify a suitable approach to symptom relief.
Does a falling PSA mean prostate cancer is cured?
Prostate-specific antigen (PSA) is a protein made by prostate cells and measured in a blood test. A fall in PSA may indicate a response but is not by itself proof of cure. The team considers the treatment goal, symptoms, PSA trend and other tests. The meaning differs between treatment after local therapy and advanced disease.
What does castration-resistant prostate cancer mean?
It means the cancer is progressing despite very low testosterone. It does not mean there are no further treatments. Additional medicines may still target androgen signalling, and other treatment types may also be considered.
Why keep hormone injections when another prostate medicine is added?
Many treatment plans require ongoing testosterone suppression while another medicine is added. The new medicine may work at a different point in the pathway. Do not stop the baseline injections unless the treating team advises it.
Can hormone therapy be combined with chemotherapy or targeted therapy?
Yes, in particular cancer settings and schedules. The sequence or combination is selected for evidence and safety. It is not simply a choice of one treatment family for the whole course of care.
How will we know whether it is helping?
Monitoring depends on the setting. In advanced cancer, symptoms, examination, markers and scans may assess control. After surgery, follow-up mainly looks for recurrence and treatment effects; there may be no visible cancer to measure.
